| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2,976.0 | 2,835.0 |
| Gross profit | 994.0 | 950.0 |
| Profit before tax | 417.0 | 121.0 |
| Net income | 294.0 | -46.0 |
| EPS (diluted, $ a share) | $0.57 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.0% |
|---|---|
| Gross margin | 33.4% |
| Operating margin | 7.6% |
10-Q filed with the SEC, NYSE: BAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Baxter International Inc: key numbers
- Share price
- $25.54Close, Nov 16
- Market cap
- $13.2B
- Shares outstanding
- 517.35MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Baxter International Inc
All →Baxter International Financial Results
Baxter International reported Q3 2026 financial results with sales of $2.98 billion, a 5% increase on both a reported and organic basis. The company achieved GAAP diluted EPS of $0.57 and raised its full-year 2026 financial outlook while completing a $600 million debt tender offer to accelerate deleveraging.
- Term
- Q3 2026
“We delivered a strong third quarter, with growth across all segments and divisions globally. We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger foundation for sustainable growth and long-term value creation.”
Andrew Hider, president and CEO